SCHEMBL4227637

SCHEMBL4227637

CS(=O)(=O)Nc1ccc(-c2ccc(C(=O)O)c(Nc3ccc4c(c3)OCO4)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.56
KIF11 P52732 1/20 0.50
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
PKM P14618 1/20 0.48
PIK3CD O00329 1/20 0.48
GRIK1 P39086 1/20 0.47
NPC1 O15118 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 1/20 0.47
PFKFB3 Q16875 1/20 0.46
ALDH1A1 P00352 2/20 0.44
HPGD P15428 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 2/20 0.43
HSD17B10 Q99714 1/20 0.43
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227799 0.86 GRIK1 (0.53) RAB9AKMT2AMEN1PKMGRIK1
SCHEMBL4223501 0.86 RAB9A (0.50) RAB9AKIF11KMT2AMEN1PKM
SCHEMBL4221471 0.81 ACLY (0.54) MAPTACLY
SCHEMBL4212903 0.80 MEN1 (0.51) RAB9AKMT2AMEN1GRIK1NPC1
SCHEMBL4219139 0.79 NPC1 (0.50) RAB9AKMT2AMEN1GRIK1NPC1
SCHEMBL4229254 0.79 ACLY (0.48) KIF11KMT2AMEN1TSHRHPGD
SCHEMBL4220093 0.79 GRIK1 (0.59) RAB9AKMT2AMEN1PKMGRIK1
SCHEMBL4218151 0.78 KMT2A (0.52) RAB9AKIF11KMT2AMEN1GRIK1
SCHEMBL4212902 0.75 CA2 (0.43) PIK3CDACLY
SCHEMBL12017944 0.75 MAPT (0.71) RAB9AKIF11KMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 RAB9A 2262/4885KIF11 1197/4885KMT2A 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.